Acrivon: Precision-Testing Your Trial Patients Before Enrolment (NASDAQ:ACRV)
Dilok Klaisataporn/iStock via Getty Images Acrivon (NASDAQ:ACRV) develops precision cancer medicines and then uses its proprietary proteomics-based patient responder identification ...